Announced details
Our company participates in an AMED research project as a collaborating company and, under an MTA (material transfer agreement), provides an iPS cell line established in-house as a comparator cell line. Our company is also positioned as the company with priority negotiation rights regarding the social implementation of drug discovery targets identified through the research.
Fujita Health University is the principal research and development institution. AMED is the Japan Agency for Medical Research and Development. The School of Medicine, Keio University, is identified as the institution from which our company originated. Other information, including location, representative, capital and year of establishment, is Not disclosed.
No impact on performance for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
Ministry of Health, Labour and Welfare, "Overview of the 2023 Patient Survey"
Estimate of global market size by a research organization (organization name: Not disclosed)
| Item | Details |
|---|---|
| Names of Products / Services Covered | iPS-Based Drug Discovery, Dopamine D2 receptor knockout iPS cell line |
| Counterparty | Japan Agency for Medical Research and Development (AMED), Fujita Health University, Keio University |
| Counterparty overview | Fujita Health University is the principal research and development institution. AMED is the Japan Agency for Medical Research and Development. The School of Medicine, Keio University, is identified as the institution from which our company originated. Other information, including location, representative, capital and year of establishment, is Not disclosed. |
| Relationship with the Company | Our company participates in an AMED research project as a collaborating company and, under an MTA (material transfer agreement), provides an iPS cell line established in-house as a comparator cell line. Our company is also positioned as the company with priority negotiation rights regarding the social implementation of drug discovery targets identified through the research. |
| Applicable area | Schizophrenia, Bipolar disorder, Mental health, Drug Discovery Research |
| Impact on Business Performance | No impact on performance for the fiscal year ending December 2026. |
| Source | Ministry of Health, Labour and Welfare, "Overview of the 2023 Patient Survey", Estimate of global market size by a research organization (organization name: Not disclosed) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to biologically stratify responses to antipsychotic drugs using patient-derived iPS cells and polygenic risk scores, thereby establishing a new drug discovery platform. Through this research, our company intends to strengthen its iPS cell-based drug discovery capabilities and expand future opportunities for research and development of therapeutic drugs and collaboration with partners.